Literature DB >> 10202044

Development of an animal model of autoimmune thyroid eye disease.

M C Many1, S Costagliola, M Detrait, F Denef, G Vassart, M C Ludgate.   

Abstract

In previous studies we have transferred thyroiditis to naive BALB/c and NOD mice with human thyrotropin (TSH) receptor (TSHR)-primed splenocytes. Because the TSHR has been implicated in the pathogenesis of thyroid eye disease (TED) we have examined the orbits of recipients of TSHR-primed T cells, generated using a TSHR fusion protein or by genetic immunization. In the NOD mice, 25 of 26 animals treated with TSHR-primed T cells developed thyroiditis with considerable follicular destruction, numerous activated and CD8+ T cells, and immunoreactivity for IFN-gamma. Thyroxine levels were reduced. Thyroiditis was not induced in controls. None of the NOD animals developed any orbital pathology. Thirty-five BALB/c mice received TSHR-primed spleen cells. Thyroiditis was induced in 60-100% and comprised activated T cells, B cells, and immunoreactivity for IL-4 and IL-10. Autoantibodies to the receptor were induced, including TSH binding inhibiting Igs. A total of 17 of 25 BALB/c orbits displayed changes consisting of accumulation of adipose tissue, edema caused by periodic acid Schiff-positive material, dissociation of the muscle fibers, the presence of TSHR immunoreactivity, and infiltration by lymphocytes and mast cells. No orbital changes or thyroiditis were observed in control BALB/c mice. We have induced orbital pathology having many parallels with human TED, only in BALB/c mice, suggesting that a Th2 autoimmune response to the TSHR may be a prerequisite for the development of TED.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10202044

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

Review 1.  Unlocking the immunological mechanisms of orbital inflammation in thyroid eye disease.

Authors:  M Ludgate; G Baker
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

2.  Cytokines, IgG subclasses and costimulation in a mouse model of thyroid autoimmunity induced by injection of fibroblasts co-expressing MHC class II and thyroid autoantigens.

Authors:  X M Yan; J Guo; P Pichurin; K Tanaka; J C Jaume; B Rapoport; S M McLachlan
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

Review 3.  New understanding of the role of cytokines in the pathogenesis of Graves' ophthalmopathy.

Authors:  R A Ajjan; A P Weetman
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

4.  Diseases as natural kinds.

Authors:  Stefan Dragulinescu
Journal:  Theor Med Bioeth       Date:  2010-10

5.  News and views: at long last, an animal model of Graves' orbitopathy.

Authors:  Rebecca S Bahn
Journal:  Endocrinology       Date:  2013-09       Impact factor: 4.736

Review 6.  Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment.

Authors:  James A Garrity; Rebecca S Bahn
Journal:  Am J Ophthalmol       Date:  2006-07       Impact factor: 5.258

Review 7.  Total thyroid ablation in Graves' orbitopathy.

Authors:  F Menconi; M Leo; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2015-03-05       Impact factor: 4.256

8.  Quantification of cells expressing the thyrotropin receptor in extraocular muscles in thyroid associated orbitopathy.

Authors:  A Boschi; Ch Daumerie; M Spiritus; C Beguin; M Senou; D Yuksel; M Duplicy; S Costagliola; M Ludgate; M C Many
Journal:  Br J Ophthalmol       Date:  2005-06       Impact factor: 4.638

9.  Poorly specific binding of thyroglobulin to orbital fibroblasts from patients with Graves' ophthalmopathy.

Authors:  S Lisi; R Botta; P Agretti; S Sellari-Franceschini; C Marcocci; A Pinchera; M Marinò
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

10.  Evidence that factors other than particular thyrotropin receptor T cell epitopes contribute to the development of hyperthyroidism in murine Graves' disease.

Authors:  P N Pichurin; Chun-Rong Chen; Y Nagayama; O Pichurina; B Rapoport; S M McLachlan
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.